The present invention relates to multi-dimensional image reconstruction and, more particularly, but not exclusively to such image reconstruction based on a diffuse radioactive source or sources.
Radiological imaging is generally carried out on a living target, which of course means a mix of tissues in close proximity, if not actually overlapping. The general procedure is to feed the patient with one or more radioactive markers prior to the imaging process. The radioactive markers are taken up by the digestive system and pass into the bloodstream. From the bloodstream the marker passes into the different tissues at varying rates depending on the tissue type. Some tissues absorb markers faster than others and some tissues absorb certain markers faster than others. Furthermore certain tissues flush out the markers faster than others, and again the rate of flushing out may also depend on the kind of marker being used.
As a result, radioactive marking in fact creates a dynamic system in the body in which the relative darkness of a given tissue is related to a time factor. The radiologist knows that if he wants a good image of say the liver following application of a given marker then he should wait a certain number of hours from application of the marker before taking the image. Even so, the liver is not differentiated clearly from the other tissues.
Examples of radiopharmaceuticals include monoclonal antibodies or other agents, e.g., fibrinogen or fluorodeoxyglucose, tagged with a radioactive isotope, e.g., Technitium-99m, Gallium-67, Thallium-201, Indium-111, Iodine-123, Iodine-125 and Fluorine-18, which may be administered orally or intravenously. The radiopharmaceuticals are designed to concentrate in the area of a tumor, and the uptake of such radiopharmaceuticals in the active part of a tumor, or other pathologies such as an inflammation, is higher and more rapid than in the tissue that neighbors the tumor. Thereafter, a radiation-emission-measuring-probe, which may be configured for extracorporeal or intracorporeal use, is employed for locating the position of the active area. Another application is the detection of blood clots with radiopharmaceuticals such as ACUTECT from Nycomed Amersham for the detection of newly formed thrombosis in veins, or clots in arteries of the heart or brain, in an emergency or operating room. Yet other applications include radioimaging of myocardial infarct using agents such as radioactive anti-myosin antibodies, radioimaging specific cell types using radioactively tagged molecules (also known as molecular imaging), etc.
The usual preferred emission for such applications is that of gamma rays, which emission is in the energy range of approximately 11–511 KeV. Beta radiation and positrons may also be detected.
Radioactive-emission imaging is performed with a radioactive-emission-measuring detector, such as a room temperature, solid-state CdZnTe (CZT) detector, which is among the more promising that is currently available. It may be configured as a single-pixel or a multi-pixel detector, and may be obtained, for example, from eV Products, a division of II–VI Corporation, Saxonburg Pa., 16056, or from IMARAD IMAGING SYSTEMS LTD., of Rehovot, ISRAEL, 76124, www.imarad.com, or from another source. Alternatively, another solid-state detector such as CdTe, HgI, Si, Ge, or the like, or a combination of a scintillation detector (such as NaI(TI), LSO, GSO, CsI, CaF, or the like) and a photomultiplier, or another detector as known, may be used.
Considering the issue in greater detail, certain biological or chemical substances such as targeted peptides, monoclonal antibodies and others, are used for tagging specific living molecules for diagnostic purposes. Ideally, these antibodies are specific to the desired type of cells, based on adhering only to specific molecular structures in which the antigene matching the antibody is highly expressed. The use of imaging devices such as a nuclear gamma probe or a visual video probe can detect radiation emanating from taggants such as radionuclei or fluorescent dies that have been appended to the antibody before being delivered to the living body. An example is a cancerous cell of a prostate tumor on whose membrane there is an over expression of the Prostate Specific Membrane Antigen (PSMA). When a monoclonal antibody (Mab) such as Capromab Pendetide (commercially available as ProstaScint manufactured by Cytogen Corp.) is labeled with radioactive Indium (In 111) and is systemically delivered to the body, the Mab is carried by the blood stream and upon reaching the prostate tissue, adheres to the PSMA. The high energy radiation photons emitted by the radioactive Indium can be detected using a nuclear camera, indicating the presence and the specific location of the tumor.
Unfortunately, given the complexity of living organisms, in many instances the same antigen is also expressed in more than just the tissue under investigation. The antibody will thus also “paint” additional tissues such as infection areas, in addition to the tissue of interest. The radioactive readings taken from this additional tissue will be falsely interpreted as tumor areas, reducing the specificity of the test being performed.
The ‘Target to Background’ ratio that characterizes every such antibody for a given target cell type is one of the major issues that determine the ability to perform proper diagnosis, and guided procedures.
Since the uptake clearance of such a marker by the various tissues (target and background) varies over time, standard diagnosis protocols usually recommend taking an image at the time at which the ratio of Target emission vs. Background emission is the highest.
In an experimental system tried out by researchers, two markers were supplied to various patients and then images were taken at successive intervals for each of the markers. Certain features in the target areas showed up clearly in all images, other features were clear for all images of one marker but faded in and faded out for the other marker, and yet other features faded in and out for both markers but at different times. The researchers were able to use their knowledge of the behaviors of the two markers with different tissues in order to identify the features in the images.
The above system therefore relies on the knowledge of the researchers to put together information received from multiple images into an understanding of what the radio-imaging shows. In the general hospital environment it is not possible to guarantee that the necessary expertise is available, at least not for the amount of time that such a system would require.
There is thus a widely recognized need for, and it would be highly advantageous to have, a radiological imaging system devoid of the above limitations.
According to one aspect of the present invention there is provided apparatus for radiation based imaging of a non-homogenous target area having distinguishable regions therein, the apparatus comprising:
an imaging unit configured to obtain radiation intensity data from said target region in the spatial dimensions and at least one other dimension, and
an image four-dimension analysis unit associated with said imaging unit for analyzing said obtained intensity data in said spatial dimension and said at least one other dimension in order to map said distinguishable regions. By image four-dimension analysis unit is meant a unit that is able to analyze image data based on the spatial dimensions plus one other dimension, such as time.
Preferably, said image four dimension analysis unit is configured to constrain image output to a subset of said mapped distinguishable regions.
Preferably, said image four-dimension analysis unit is configured to use said constraining to increase a resolution of said image output.
Preferably, the distinguishable regions have differential takeup characteristics over time for radioactive markers and said multi-dimensional data includes a time component, said image analysis unit being configured to compare changes in detected intensity over time with said takeup characteristics in order to carry out said mapping.
Preferably, at least two radioactive markers are applied to said target region, each of said markers having different takeup characteristics for respective ones of said regions, and each of said markers producing respectively distinguishable radiation, said image analysis unit being configured to use distinguishability of the radiation between said markers as an additional dimension in order to carry out said mapping.
Preferably, at least two radioactive markers are applied to said target region, each of said markers having different takeup characteristics for respective ones of said regions, and each of said markers producing respectively distinguishable radiation, said image analysis unit being configured to use distinguishability of the radiation between said markers as said at least one other dimension in order to carry out said mapping.
Preferably, said image analysis unit is configured to use said mapping to generate an image comprising said regions as distinct entities.
Preferably, said image analysis unit is configured to use said mapping to generate an image showing only a subset of said regions and to exclude at least one other of said regions.
Preferably, said regions at least partially overlap, said image analysis unit being configured to show radiation due to a subset of said regions and to exclude radiation from at least one other of said regions as noise.
Preferably, said image analysis unit is configured to use said mapping to generate an image comprising said regions as distinct entities.
Preferably, said image analysis unit is configured to use said mapping to generate an image showing only a subset of said regions and to exclude at least one other of said regions.
Preferably, said regions at least partially overlap, said image analysis unit being configured to show radiation due to a subset of said regions and to exclude radiation from at least one other of said regions as noise.
Preferably, said imaging unit comprises at least one directional Geiger counter.
Preferably, said imaging unit comprises a plurality of directional Geiger counters.
Preferably, said imaging unit comprises a controller for directing said Geiger counter to take images from a set of locations optimized to obtain three-dimensional spatial data for a given target.
Preferably, said non-homogenous target area is a region of living tissue, and said distinguishable regions are at least one of a group comprising: different tissues, different organs, blood and organ tissue, and tissue regions of differential pathologies.
Preferably, one of said radioactive markers is Thallium-201 and another of said radioactive markers is technetium 99.
Preferably, said image analysis unit is configured to ignore image data as being from outside said target area if said image data does not conform to at least one of said takeup characteristics.
The apparatus may be configured to use said mapping to identify at least one region of low emissivity, thereby to concentrate imaging resources on said identified region.
Preferably, said imaging is via voxels of said target area and wherein said concentrating imaging resources comprises merging voxels of said identified region.
Preferably, said concentrating resources comprises concentrating resources of said imaging unit on said identified region.
Preferably, said mapping comprises a first mapping to identify an organ and a second mapping constrained within said organ.
According to a second aspect of the present invention, there is provided a method for constraining image data obtained from a non-homogenous target area having a plurality of distinct regions using at least one radioactive marker, the method comprising:
obtaining radiation intensity data from said target area in the spatial dimensions and at least one other dimension, and
analyzing said radiation intensity data using said dimensions in order to classify data pertaining to respective distinct regions and to produce an output constrained to a subset of said distinct regions.
Preferably, said at least one radioactive marker has a time absorption characteristic which is different for ones of said distinct regions and wherein said at least one other dimension is a time dimension.
Preferably, there are provided at least two radioactive markers, each having respectively different time absorption characteristics for each of said distinct regions, and wherein said at least one other dimension is a time dimension.
Preferably, there are provided at least two radioactive markers, each producing a distinct signal and each respectively having different time absorption characteristics for each of said distinct regions, and wherein said at least one other dimension is a dimension indicating individual markers.
Preferably, there are provided at least two radioactive markers, each producing a distinct signal and each respectively having different time absorption characteristics for each of said distinct regions, and wherein said at least one other dimension comprises a time dimension and a dimension indicating individual markers.
Preferably, said classifying identifies at least one region of low emissivity, the method further comprising concentrating imaging resources on said identified region.
Preferably, said imaging is via voxels of said target area and said concentrating imaging resources comprises merging voxels of said identified region.
Preferably, said concentrating resources comprises concentrating resources of said imaging unit on said identified region.
Preferably, said classifying comprises a first classification to identify an organ and a second classification constrained within said organ.
According to a third aspect of the present invention there is provided apparatus for radiation based imaging of a non-homogenous target area having distinguishable regions therein, the apparatus comprising:
an imaging unit configured to obtain radiation intensity data from said target region in the spatial dimensions and at least one other dimension,
an image analysis unit associated with said imaging unit for analyzing said obtained intensity data in said spatial dimension and said at least one other dimension in order to map said distinguishable regions, and using said mapping to control use of imaging resources.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The materials, methods, and examples provided herein are illustrative only and not intended to be limiting.
Implementation of the method and system of the present invention involves performing or completing certain selected tasks or steps manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of preferred embodiments of the method and system of the present invention, several selected steps could be implemented by hardware or by software on any operating system of any firmware or a combination thereof. For example, as hardware, selected steps of the invention could be implemented as a chip or a circuit. As software, selected steps of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In any case, selected steps of the method and system of the invention could be described as being performed by a data processor, such as a computing platform for executing a plurality of instructions.
The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in order to provide what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
In the drawings:
The present embodiments comprise an apparatus and a method for radiation based imaging of a non-homogenous target area having regions of different material or tissue type or pathology. The imaging uses multi-dimensional data of the target area in order to distinguish the different regions. Typically the multi-dimensional data involves time as one of the dimensions. A radioactive marker has particular time-absorption characteristics which are specific for the different tissues, and the imaging device is programmed to constrain its imaging to a particular characteristic.
The result is not merely an image which concentrates on the tissue of interest but also, because it is constrained to the tissue of interest, is able to concentrate imaging resources on that tissue and thus produce a higher resolution image than the prior art systems which are completely tissue blind.
The principles and operation of a radiological imaging system according to the present invention may be better understood with reference to the drawings and accompanying description.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
Reference is now made to
If the counter is now moved to different positions over the surface of the target then the data from the different positions can be built up into a low resolution two-dimensional image.
One way of increasing the resolution of the Geiger counter is to make it smaller. Then the cone, whilst retaining the same geometry, gives higher resolution data.
The detector takes (yt)t=1T samples to form a data set, which would typically be a two-dimensional image of the target from a given direction.
Reference is now made to
Reference is now made to
The principle on which the present embodiments are based is as follows: Considering the graphs in
Reference is now made to
In a preferred embodiment, the signals received from the individual Geiger counters are summed to form a three-dimensional image of the target area. The skilled person will appreciate that the system could also be based on a two-dimensional image. In either case, the signals are fed to an image analyzer 28, where the signals are analyzed to form images.
In the preferred embodiments, the image analyzer is able to use the marker take up characteristics to compare successive images and identify regions of particular interest, and then to concentrate imaging resources on those regions. That is to say the image analyzer is in fact able to control further operation of the imager.
Reference is now made to
It will be appreciated that in many cases two types of tissue may be superimposed, of which only one of the tissues is of interest. In this case it is of equal importance both to exclude the one tissue that is not of interest and to include the tissue that is of interest. It may be that the best marker for one tissue may not be the best marker for the other tissue. The system as described with respect to
As a result the image analysis unit is able to produce a final result treating the various tissue regions as separate entities. Furthermore, as the system is aware of the regions as entities it is able to further direct the imaging process to concentrate on the regions of interest.
An example in which regions at least partially overlap is the heart. Generally, scans of the heart are interested in the muscular walls of the heart. Although the chambers of the heart are filled with blood, any signal coming from the blood is in fact noise to this kind of scan. It is therefore advantageous to carry out an imaging process which is able to positively identify signals from the muscular heart walls and at the same time exclude the blood.
Referring now to
In the above example, two regions were of respectively positive and negative interest, meaning one for concentrating on and the other for filtering out. It will be appreciated that several regions or several tissue types may be of positive interest or there may be any combination of regions with just one being of positive interest. Alternatively all regions may be of positive interest but importance may be attached to discriminating between the different signals from the different regions.
The system is able to use the mapping to generate an image comprising the different tissue regions as distinct entities. As a consequence of the mapping process, the system is able to be aware electronically of the different regions and thus control both the imaging head and the analysis unit to concentrate their resources on specific regions. The result is greater resolution for the regions of interest.
The preferred embodiments may be used to expand the information obtained from the markers, using either or both of examining the kinetics of the markers over time and using several markers concurrently.
In order to increase the specificity of the test, additional second substances (“secondary substances”), with reactivity and pharmaco-kinetics differing from those of the first substance can be used in order to enhance the differentiation between the different pathologies, as explained above with respect to
Upon reading the radioactive signals emanating from the voxels stemming from different substances at different time instances, it is possible to build for every voxel a multi dimensional data matrix Sjk whose elements are intensity readings taken at instances K resulting from the interaction of Substance J. Examination of every voxel of tissue in this multidimensional space quantifies the temporal and specific reaction of the tissue to different substances and thus increases the probability of specific detection of different pathologies. Furthermore, standard image processing techniques can be used in order to more accurately define the spatial location of different pathologies.
In addition to the method above, spatial properties that reflect typical relationships between neighboring voxels may also be a criteria and represented as part of the pattern of the tissue type.
Reference is now made to
Reference is now made to
If there are still not enough photons, or there are not enough detectors, then another way of pooling resources is to merge neighboring voxels (or regions). Such a procedure may reduce resolution, but will increase the overall number of photons for that merged region, and thus enable better classification of that region based on a more reliable photon count. Such a compromise enables analysis of the same collected data by ways that would allow high resolution where there are enough photons and lower resolutions where there are less while maintaining reliability of the analysis.
Again the tissue regions may be identified using multiple markers.
The above-described embodiment may lead to controlled sensitivity levels, currently not available with radioimaging.
The concept of using multiple antibodies can be used for therapy purposes, as in the following:
The specificity of a single antibody carrying a drug (or radioactive therapy) determines the chance for non-target tissue to receive the drug, and thus be subject to any toxicity of the drug. In cases where there are several antibodies, each with limited specificity, but with affinity to different ‘background’ tissue, a combination of antibodies may be used to improve the overall specificity, and thus to reduce overall toxicity and enable higher efficacy of treatment.
For example, if a first antibody (A1) based drug binds to the target N1 folds its affinity to the closest non-target tissue (B1), and a second antibody (A2) with similar drug has target affinity which is N2 folds higher than its closest non-target tissue (B2), then using a merged therapy will enable better target vs. non-target specificity, which is better than N1 and N2 (assuming B1 and B2 are different).
In a more generalized embodiment, the system may include a signal analysis module, including a library of patterns that are typical for every cell type. Each type of cells has one or more patterns associated with it, and the pattern determines how a set of markers injected according to a specific protocol (dosage, time, etc) may be expressed in that cell type. The analysis includes classification of the readings from each voxel based on correlation, or other statistical tools for assessing the most probable tissue classification for each voxel.
Since there may be several cell types for a given disease (e.g. cancer may show in several forms), the algorithm may be optimized to determine the exact tissue type per voxel or region. Alternatively, the algorithm may be optimized to determine the general property of diseased/non-diseased, while taking the specific classification only as a factor in the statistical analysis.
It should be noted that the system may allow for various protocols for administering the markers, where injection of the various markers may be simultaneous, or multiple injections at various times, as various markers have different lifetime in the circulation.
The issue of generating imaging using two or more markers is now considered mathematically.
An intensity distribution I, conventionally defined in terms of radioactive emissions per seconds, is now redefined as a vector of distributions over the volume U, forming our input space. Each dimension of the vector is a different one of the radiopharmaceuticals. The universal set U comprises a set of basic elements u (e.g., pixels in two dimensional spaces, voxels in three dimensional spaces), and I(u) is the intensity in a given basic element uεU. For j radiopharmaceuticals this becomes l(u)(j,t) An inverse (or reconstruction) problem arises when one cannot sample directly from I, but can sample from a given set of views Φ. A projection φεΦ is defined by the set of probabilities {φ(u):uεU}, where φ(u) is the probability of detecting a radioactive emission from a voxel u, as defined by viewing parameters, such as the physical and geometrical properties of the detecting unit, as well as the attenuation parameters of the viewed volume U, and the time parameters. A measurement is obtained by choosing a view φεΦ, and then sampling according to the viewing parameters.
For j radiopharmaceuticals or markers and k detectors, the probability of seeing a particle becomes φjk(u)
In the following analysis, I is the intensity of a radioactive substance, and the viewing parameters include the geometrical properties of a collimated detecting unit and the detecting unit's position and orientation with respect to volume U. The number of radioactive emissions counted by the detecting unit within a time interval is a Poisson distribution, where φ(u) is the detection probability of a photon emitted from voxel uεU and the mean of the distribution is the weighted sum ΣuεUφ(u)I(u).
For the case of the kth detector a measurement Yk=ΣuεU Xt(u), where X(U) is a Poisson distribution.
X(j,k,t)(u)=I(i,t)(u).φ(u)jk(u).
Where Y(j,k,t)=ΣX(j,k,t)(u).
Hence Y(j,k,t))=Poisson(Y(j,k,t))
The projection set is thus defined by a matrix Φ, whose rows are the projections of the chosen views. I is a vector of densities (specified per each element in U), and ΦI is a vector of respective effective intensity levels for the views in the set. A vector of measurements y is obtained by a random sample from each view (according to the associated Poisson distribution). As discussed above, there are various known reconstruction methods that provide estimators for I given the projections Φ and the measurements y.
Using the above mathematics the problem is solved (an image created) one of the vectors say once an hour. The rates of change are determined. Simultaneously the problem is solved for another of the vectors at similar time intervals and the rates of change are determined. Then a stage of cross-identification is carried out between the two images, so that wanted tissues as identified by each image minus unwanted tissues identified by each image are concentrated on to form a new image. Cross-identification may be an iterative process.
In the example given above of the imaging of the heart using one blood marker and one muscular tissue marker, the areas identified by the blood marker are subtracted. The areas identified by the muscle marker are added, and those tissues not identified by either are likewise ignored as being signals from outside the target region.
The non-homogenous target area is typically a region of living tissue, generally belonging to a patient. The distinguishable regions within can be different tissues, different organs, a mixture of blood and organ tissue as with the above example of the heart, or tissue regions exhibiting differential pathologies.
It is expected that during the life of this patent many relevant markers, radiological imaging devices and two and three dimensional imaging systems will be developed and the scopes of the corresponding terms herein, are intended to include all such new technologies a priori.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.
The present application claims priority from U.S. Provisional Patent Application No. 60/535,830 filed Jan. 13, 2004, the contents of which are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
2776377 | Anger | Jan 1957 | A |
3340866 | Nöller | Sep 1967 | A |
3684887 | Hugonin | Aug 1972 | A |
3719183 | Schwartz | Mar 1973 | A |
3739279 | Hollis | Jun 1973 | A |
3971362 | Pope et al. | Jul 1976 | A |
4278077 | Mizumoto | Jul 1981 | A |
4364377 | Smith | Dec 1982 | A |
4521688 | Yin | Jun 1985 | A |
4674107 | Urban et al. | Jun 1987 | A |
4689041 | Corday et al. | Aug 1987 | A |
4689621 | Kleinberg | Aug 1987 | A |
4773430 | Porath | Sep 1988 | A |
4828841 | Porter et al. | May 1989 | A |
4844067 | Ikada et al. | Jul 1989 | A |
4844076 | Lesho et al. | Jul 1989 | A |
4893013 | Denen et al. | Jan 1990 | A |
4928250 | Greenberg et al. | May 1990 | A |
4929832 | Ledley | May 1990 | A |
4959547 | Carroll et al. | Sep 1990 | A |
5014708 | Hayashi et al. | May 1991 | A |
5032729 | Charpak | Jul 1991 | A |
5033998 | Corday et al. | Jul 1991 | A |
5070878 | Denen | Dec 1991 | A |
5119818 | Carroll et al. | Jun 1992 | A |
5151598 | Denen | Sep 1992 | A |
5170055 | Carroll et al. | Dec 1992 | A |
5170789 | Narayan et al. | Dec 1992 | A |
5243988 | Sieben et al. | Sep 1993 | A |
5246005 | Carroll et al. | Sep 1993 | A |
5249124 | DeVito | Sep 1993 | A |
5279607 | Schentag et al. | Jan 1994 | A |
5299253 | Wessels | Mar 1994 | A |
5307808 | Dumoulin et al. | May 1994 | A |
5383456 | Arnold et al. | Jan 1995 | A |
5395366 | D'Andrea | Mar 1995 | A |
5399868 | Jones et al. | Mar 1995 | A |
5415181 | Hogrefe et al. | May 1995 | A |
5441050 | Thurston et al. | Aug 1995 | A |
5448073 | Jeanguillaume | Sep 1995 | A |
5475219 | Olson | Dec 1995 | A |
5484384 | Fearnot | Jan 1996 | A |
5489782 | Wernikoff | Feb 1996 | A |
5493595 | Schoolman | Feb 1996 | A |
5604531 | Iddan et al. | Feb 1997 | A |
5617858 | Taverna et al. | Apr 1997 | A |
5635717 | Popescu | Jun 1997 | A |
5657759 | Essen-Moller | Aug 1997 | A |
5682888 | Olson et al. | Nov 1997 | A |
5690691 | Chen et al. | Nov 1997 | A |
5694933 | Madden et al. | Dec 1997 | A |
5716595 | Goldenberg | Feb 1998 | A |
5727554 | Kalend et al. | Mar 1998 | A |
5729129 | Acker | Mar 1998 | A |
5732704 | Thurston et al. | Mar 1998 | A |
5744805 | Raylman et al. | Apr 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5842977 | Lesho et al. | Dec 1998 | A |
5846513 | Carroll et al. | Dec 1998 | A |
5857463 | Thurston et al. | Jan 1999 | A |
5871013 | Wainer et al. | Feb 1999 | A |
5880475 | Oka et al. | Mar 1999 | A |
5900533 | Chou | May 1999 | A |
5916167 | Kramer et al. | Jun 1999 | A |
5928150 | Call | Jul 1999 | A |
5932879 | Raylman et al. | Aug 1999 | A |
5939724 | Eisen et al. | Aug 1999 | A |
5984860 | Shan | Nov 1999 | A |
5987350 | Thurston | Nov 1999 | A |
5993378 | Lemelson | Nov 1999 | A |
6002480 | Izatt et al. | Dec 1999 | A |
6082366 | Andra et al. | Jul 2000 | A |
6107102 | Ferrari | Aug 2000 | A |
6115635 | Bourgeois | Sep 2000 | A |
6132372 | Essen-Moller | Oct 2000 | A |
6135955 | Madden et al. | Oct 2000 | A |
6173201 | Front | Jan 2001 | B1 |
6205347 | Morgan et al. | Mar 2001 | B1 |
6212423 | Krakovitz | Apr 2001 | B1 |
6240312 | Alfano et al. | May 2001 | B1 |
6242743 | DeVito et al. | Jun 2001 | B1 |
6261562 | Xu et al. | Jul 2001 | B1 |
6263229 | Atalar et al. | Jul 2001 | B1 |
6271524 | Wainer et al. | Aug 2001 | B1 |
6271525 | Majewski et al. | Aug 2001 | B1 |
6280704 | Schutt et al. | Aug 2001 | B1 |
6324418 | Crowley et al. | Nov 2001 | B1 |
6346706 | Rogers et al. | Feb 2002 | B1 |
6368331 | Front et al. | Apr 2002 | B1 |
6407391 | Mastrippolito et al. | Jun 2002 | B1 |
6426917 | Tabanou et al. | Jul 2002 | B1 |
6429431 | Wilk | Aug 2002 | B1 |
6431175 | Penner et al. | Aug 2002 | B1 |
6453199 | Kobozev | Sep 2002 | B1 |
6516213 | Nevo | Feb 2003 | B1 |
6525320 | Juni | Feb 2003 | B1 |
6525321 | Juni | Feb 2003 | B2 |
6560354 | Maurer et al. | May 2003 | B1 |
6567687 | Front et al. | May 2003 | B2 |
6584348 | Glukhovsky | Jun 2003 | B2 |
6587710 | Wainer | Jul 2003 | B1 |
6592520 | Peszynski et al. | Jul 2003 | B1 |
6607301 | Glukhovsky et al. | Aug 2003 | B1 |
6611141 | Schulz et al. | Aug 2003 | B1 |
6614453 | Suri et al. | Sep 2003 | B1 |
6628983 | Gagnon | Sep 2003 | B1 |
6628984 | Weinberg | Sep 2003 | B2 |
6662036 | Cosman | Dec 2003 | B2 |
6748259 | Benaron et al. | Jun 2004 | B1 |
20020072784 | Sheppard, Jr. et al. | Jun 2002 | A1 |
20020085748 | Baumberg | Jul 2002 | A1 |
20030001837 | Baumberg | Jan 2003 | A1 |
20030013966 | Barnes et al. | Jan 2003 | A1 |
20030063787 | Natanzon et al. | Apr 2003 | A1 |
20030191430 | D'Andrea et al. | Oct 2003 | A1 |
20030208117 | Shwartz et al. | Nov 2003 | A1 |
20040015075 | Kimchy et al. | Jan 2004 | A1 |
20040054248 | Kimchy et al. | Mar 2004 | A1 |
20040054278 | Kimchy et al. | Mar 2004 | A1 |
20040116807 | Amrami et al. | Jun 2004 | A1 |
Number | Date | Country |
---|---|---|
WO 9200402 | Sep 1992 | WO |
WO 9903003 | Jan 1999 | WO |
WO 0031522 | Feb 2000 | WO |
WO 0018294 | Jun 2000 | WO |
WO 02058531 | Jan 2002 | WO |
WO 0216965 | Feb 2002 | WO |
WO 2004042546 | May 2004 | WO |
Number | Date | Country | |
---|---|---|---|
20050205792 A1 | Sep 2005 | US |
Number | Date | Country | |
---|---|---|---|
60535830 | Jan 2004 | US |